PLP1 and myeloid sarcoma: These data are consistent with the clinical observation of an inflammation decline from the relapsing–remitting MS to the progressive MS and let us hypothesize that an immune/inflammatory suppression, while relevant for the PLP–EAE model, is not prominently involved in the ASO-induced remyelinating and pain-relieving activity in the chronic model.